HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin - PubMed (original) (raw)

doi: 10.1038/ng.379. Epub 2009 May 31.

Peter T Donaldson, Pallav Bhatnagar, Yufeng Shen, Itsik Pe'er, Aris Floratos, Mark J Daly, David B Goldstein, Sally John, Matthew R Nelson, Julia Graham, B Kevin Park, John F Dillon, William Bernal, Heather J Cordell, Munir Pirmohamed, Guruprasad P Aithal, Christopher P Day; DILIGEN Study; International SAE Consortium

Affiliations

• PMID: 19483685
• DOI: 10.1038/ng.379

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

Ann K Daly et al. Nat Genet. 2009 Jul.

Abstract

Drug-induced liver injury (DILI) is an important cause of serious liver disease. The antimicrobial agent flucloxacillin is a common cause of DILI, but the genetic basis for susceptibility remains unclear. We conducted a genome-wide association (GWA) study using 866,399 markers in 51 cases of flucloxacillin DILI and 282 controls matched for sex and ancestry. The GWA showed an association peak in the major histocompatibility complex (MHC) region with the strongest association (P = 8.7 x 10(-33)) seen for rs2395029[G], a marker in complete linkage disequilibrium (LD) with HLA-B*5701. Further MHC genotyping, which included 64 flucloxacillin-tolerant controls, confirmed the association with HLA-B*5701 (OR = 80.6, P = 9.0 x 10(-19)). The association was replicated in a second cohort of 23 cases. In HLA-B*5701 carrier cases, rs10937275 in ST6GAL1 on chromosome 3 also showed genome-wide significance (OR = 4.1, P = 1.4 x 10(-8)). These findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.

PubMed Disclaimer

Similar articles

• Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles.
  Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, Andrade RJ, Bjornsson E, Dillon JF, Hallberg P, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Wadelius M, Shen Y, Nelson MR, Daly AK; International Drug-Induced Liver Injury Consortium (iDILIC). Nicoletti P, et al. Clin Pharmacol Ther. 2019 Jul;106(1):245-253. doi: 10.1002/cpt.1375. Epub 2019 Mar 19. Clin Pharmacol Ther. 2019. PMID: 30661239
• The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype.
  Vera JH, Naous N, Mackie N, Winston A, Cooke G. Vera JH, et al. AIDS. 2013 Jan 28;27(3):484-5. doi: 10.1097/QAD.0b013e32835a9a0d. AIDS. 2013. PMID: 23032409
• Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
  Petros Z, Makonnen E, Aklillu E. Petros Z, et al. OMICS. 2017 Mar;21(3):123-131. doi: 10.1089/omi.2017.0006. Epub 2017 Feb 16. OMICS. 2017. PMID: 28253087 Free PMC article.
• Genetic association studies in drug-induced liver injury.
  Daly AK, Day CP. Daly AK, et al. Semin Liver Dis. 2009 Nov;29(4):400-11. doi: 10.1055/s-0029-1240009. Epub 2009 Oct 13. Semin Liver Dis. 2009. PMID: 19826974 Review.
• Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
  Kaniwa N, Saito Y. Kaniwa N, et al. J Hum Genet. 2013 Jun;58(6):317-26. doi: 10.1038/jhg.2013.37. Epub 2013 May 2. J Hum Genet. 2013. PMID: 23635947 Review.

Cited by

• Human leucocyte antigen B*57.01 allelic gene is uncommon in Nigerians: An implication for antiretroviral therapy among the HIV/AIDS cohort.
  Owojuyigbe TO, Bolarinwa RA, Adesina AS, Ademosun AA, Akinola NO. Owojuyigbe TO, et al. Indian J Med Res. 2024 May;159(5):530-533. doi: 10.25259/ijmr_1263_23. Indian J Med Res. 2024. PMID: 39382409 Free PMC article. No abstract available.
• Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs.
  Chen VL, Rockey DC, Bjornsson ES, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network Investigators. Chen VL, et al. Drug Saf. 2024 Sep 24. doi: 10.1007/s40264-024-01486-6. Online ahead of print. Drug Saf. 2024. PMID: 39317916
• Hepatic immune regulation and sex disparities.
  Burra P, Zanetto A, Schnabl B, Reiberger T, Montano-Loza AJ, Asselta R, Karlsen TH, Tacke F. Burra P, et al. Nat Rev Gastroenterol Hepatol. 2024 Sep 5. doi: 10.1038/s41575-024-00974-5. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39237606 Review.
• Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions.
  Molatefi R, Talebi S, Samei A, Roshanravan N, Manshouri S, Hashemi B, Ghobadi Dana V, Mosharkesh E, Bahar MA, Khajoei S, Seif F. Molatefi R, et al. Heliyon. 2024 Jul 2;10(14):e33976. doi: 10.1016/j.heliyon.2024.e33976. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39100437 Free PMC article. Review.
• Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population.
  Chou WH, Chen LC, Wong HS, Chao CH, Chu HW, Chang WC. Chou WH, et al. Biomark Res. 2024 May 3;12(1):46. doi: 10.1186/s40364-024-00591-z. Biomark Res. 2024. PMID: 38702819 Free PMC article.

References

1. 1. Gastroenterology. 1999 Nov;117(5):1181-6 - PubMed
2. 1. Methods Mol Biol. 2006;320:193-207 - PubMed
3. 1. Clin Ther. 2001 Oct;23(10):1603-14 - PubMed
4. 1. Pharmacogenomics J. 2009 Feb;9(1):23-33 - PubMed
5. 1. Blood. 2006 Nov 15;108(10):3397-405 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • H1 Connect
  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Pharmacogenomics Knowledge Base

• Research Materials

  • NCI CPTC Antibody Characterization Program